{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:11:33Z","timestamp":1777990293801,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.thromres.2011.11.041","type":"journal-article","created":{"date-parts":[[2011,12,17]],"date-time":"2011-12-17T01:13:19Z","timestamp":1324084399000},"page":"426-433","source":"Crossref","is-referenced-by-count":64,"title":["Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy \u2013 A European Perspective"],"prefix":"10.1016","volume":"129","author":[{"given":"Adriano","family":"Alatri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Elina","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Koster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle A.","family":"Kozek-Langenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus D.","family":"Lanc\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Link","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn D.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per M.","family":"Sandset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Spanjersberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Spannagl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2011.11.041_bb0005","first-page":"247","article-title":"Heparin-induced thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen","volume":"71","author":"Greinacher","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0010","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4","volume":"83","author":"Kelton","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI116987","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells","volume":"93","author":"Visentin","year":"1994","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.041_bb0020","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","article-title":"Heparin-induced thrombocytopenia: laboratory studies","volume":"72","author":"Kelton","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0025","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","article-title":"Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia","volume":"84","author":"Warkentin","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0030","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1378\/chest.127.2_suppl.9S","article-title":"The pathophysiology of heparin-induced thrombocytopenia. Biological basis for treatment","volume":"127","author":"Kelton","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2011.11.041_bb0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V96.1.182","article-title":"Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified antiPF4-heparin antibodies to platelets and the resultant platelet activation","volume":"96","author":"Newman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0040","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2011.11.041_bb0045","series-title":"Heparin-induced thrombocytopenia","article-title":"Clinical Picture of heparin-induced thrombocytopenia","author":"Warkentin","year":"2008"},{"key":"10.1016\/j.thromres.2011.11.041_bb0050","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMcp052967","article-title":"Heparin-induced thrombocytopenia","volume":"355","author":"Arepally","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2011.11.041_bb0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and Prevention of Heparin-Induced Thrombocytopenia American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.041_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11936-008-0013-1","article-title":"Heparin-induced thrombocytopenia: 2008 update","volume":"10","author":"Bartholomew","year":"2008","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.thromres.2011.11.041_bb0065","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1378\/chest.08-2830","article-title":"Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management","volume":"135","author":"Shantsila","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.thromres.2011.11.041_bb0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1592\/phco.23.6.745.32188","article-title":"Frequency of heparin-induced thrombocytopenia in critical care patients","volume":"23","author":"Verma","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.041_bb0435","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients. A multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2011.11.041_bb0080","first-page":"548","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"69","author":"Ebell","year":"2004","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/j.thromres.2011.11.041_bb0085","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FJC.0b013e3181926928","article-title":"Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with Argatroban: a retrospective study","volume":"52","author":"Hursting","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.thromres.2011.11.041_bb0440","series-title":"Heparin-induced thrombocytopenia","year":"2008"},{"key":"10.1016\/j.thromres.2011.11.041_bb0445","series-title":"Immunogenic but effective: the HIT-fondaparinux brain puzzler","author":"Greinacher","year":"2011"},{"key":"10.1016\/j.thromres.2011.11.041_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.athoracsur.2006.05.077","article-title":"Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: singel-institution experience in patients 358 consecutive patients","volume":"83","author":"Koster","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.thromres.2011.11.041_bb0105","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","article-title":"Impact of patient population art risk for heparin-induced thrombocytopenia","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2011.11.041_bb0110","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2005-11-012450","article-title":"Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia","volume":"108","author":"Warkentin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00007691-198306000-00010","article-title":"Heparin-induced thrombocytopenia: a prospective evaluation of 211 patients","volume":"5","author":"Cipolle","year":"1983","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.thromres.2011.11.041_bb0120","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2005-03-0912","article-title":"BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study","volume":"106","author":"Prandoni","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0125","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1592\/phco.26.10.1438","article-title":"Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism","volume":"26","author":"Creekmore","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.thromres.2011.11.041_bb0130","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2005-05-1824","article-title":"Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of its lower frequency og heparin-induced thrombocytopenia","volume":"106","author":"Greinacher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2141.2005.05381.x","article-title":"Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies","volume":"128","author":"Pouplard","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2011.11.041_bb0140","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0145","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.34.6.736","article-title":"Heparin-induced thrombocytopenia in patients with cerbrovascular ischemic disease","volume":"34","author":"Ramirez-Lassepas","year":"1984","journal-title":"Neurology"},{"issue":"suppl 2","key":"10.1016\/j.thromres.2011.11.041_bb0150","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0049-3848(07)70143-3","article-title":"Cancer, thrombosis and heparin-induced thrombocytopenia","volume":"120","author":"Prandoni","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2011.11.041_bb0155","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.thromres.2011.11.041_bb0160","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0037-1614206","article-title":"Heparin-induced thrombocytopenia: towards consensus","volume":"79","author":"Warkentin","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0170","first-page":"72","article-title":"Heparin-induced thrombocytopenia","volume":"85","author":"Fabris","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2011.11.041_bb0175","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.5858\/2002-126-1415-PCMALT","article-title":"Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the College of American Pathologists","volume":"126","author":"Warkentin","year":"2002","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.thromres.2011.11.041_bb0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1160\/TH04-12-0825","article-title":"Clinical features of geparin-induced thrombocytopenia including risk factors for thrombosis","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0450","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/asheducation-2006.1.408","article-title":"Think of HIT","author":"Warkentin","year":"2006","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.041_bb0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/17474086.1.1.75","article-title":"Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis","volume":"1","author":"Greinacher","year":"2008","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.thromres.2011.11.041_bb0195","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1378\/chest.127.5.1857","article-title":"Heparin-induced skin lesions and other unusual sequelae of the heparin-induced syndrome: a nested cohort study","volume":"127","author":"Warkentin","year":"2005","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.thromres.2011.11.041_bb0200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1503\/cmaj.081729","article-title":"Incidence and cause of heparin-induced skin lesions","volume":"181","author":"Schindewolf","year":"2009","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.041_bb0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/14740330902778180","article-title":"Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes","volume":"8","author":"Warkentin","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.thromres.2011.11.041_bb0455","first-page":"182a","article-title":"Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT","volume":"92","author":"Warkentin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0215","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.041_bb0220","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccc.2005.03.003","article-title":"Heparin, Low Molecular Weight Heparin, and Heparin-Induced Thrombocytopenia in the ICU","volume":"21","author":"Warkentin","year":"2005","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.thromres.2011.11.041_bb0225","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.21032","article-title":"What is the potential for overdiagnosis of heparin-induced thrombocytopenia?","volume":"82","author":"Lo","year":"2007","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.041_bb0230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11239-009-0425-0","article-title":"Heparin\u2013platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study","volume":"30","author":"Levine","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2011.11.041_bb0235","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajcp\/111.5.700","article-title":"Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4-enzyme-linked immunoabsorbent assay for diagnosis of hepartin-induced thrombocytopenia","volume":"111","author":"Pouplard","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.thromres.2011.11.041_bb0240","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1538-7836.2009.03465.x","article-title":"Prospective evaluation of PF4\/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia","volume":"7","author":"Bakchol","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2011.11.041_bb0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1538-7836.2009.03385.x","article-title":"Heparin-induced thrombocytopenia","volume":"7","author":"Greinacher","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","article-title":"A diagnostic test for heparin-induced thrombocytopenia","volume":"67","author":"Sheridan","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.11.041_bb0255","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1538-7836.2006.01932.x","article-title":"Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia : comparison with reference method by [14C]-serotonin","volume":"4","author":"Fouassier","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0260","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0037-1614536","article-title":"First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with PF4\/heparin ELISA","volume":"81","author":"Eichler","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0265","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1537-2995.1994.34594249047.x","article-title":"Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4\/heparin enzyme-linked immunoabsorbent assay","volume":"34","author":"Greinacher","year":"1994","journal-title":"Transfusion"},{"issue":"suppl 1","key":"10.1016\/j.thromres.2011.11.041_bb0270","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/107602969900500105","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"5","author":"Walenga","year":"1999","journal-title":"Clin Appl Thrombosis\/Hemostasis"},{"issue":"suppl 5","key":"10.1016\/j.thromres.2011.11.041_bb0275","first-page":"251","article-title":"Pharmacokinetic studies of argidipine (MD-805) in human \u2013 concentrations of argidipine and its metabolites in plasma, urine, feces during and after drip intravenous infusion","volume":"14","author":"Izawa","year":"1986","journal-title":"Jpn J Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.041_bb0280","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2011.11.041_bb0285","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3999\/jscpt.12.359","article-title":"Phase one study of synthetic antithrombin agent (MD-805) single and multiple admnistration studies","volume":"12","author":"Nagasawa","year":"1981","journal-title":"Jpn J Pharmacol Ther"},{"key":"10.1016\/j.thromres.2011.11.041_bb0290","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0049-3848(02)00049-X","article-title":"Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia","volume":"105","author":"Walenga","year":"2002","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.041_bb0295","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1345\/aph.1C443","article-title":"Argatroban dosing in patients with heparin-induced thrombocytopenia","volume":"37","author":"Verme-Gibboney","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.041_bb0300","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1345\/aph.1K434","article-title":"Reduced argatroban doses after coronary artery bypass graft surgery","volume":"42","author":"Hoffman","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.thromres.2011.11.041_bb0460","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(81)91279-1","article-title":"Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion","volume":"101","author":"Okamoto","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.041_bb0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1527-3466.1991.tb00415.x","article-title":"Argatroban, a selective, potent thrombin inihibitor","volume":"9","author":"Bush","year":"1991","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.thromres.2011.11.041_bb0315","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2011.11.041_bb0320","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.thromres.2011.11.041_bb0465","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1592\/phco.20.9.756.35194","article-title":"Comparison of anticoagulant effects and safety of argatroban in healthy subjects","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2011.11.041_bb0470","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000081506","article-title":"Ecarin chromogenic assay \u2013 a new method for quantitative determination of direct thrombin inhibitors","volume":"33","author":"Lange","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.041_bb0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1345\/aph.1L213","article-title":"Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia","volume":"43","author":"Ansara","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.thromres.2011.11.041_bb0340","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1H569","article-title":"Argatroban anticoagulation in critically ill patients","volume":"41","author":"Beiderlinden","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.041_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1345\/aph.1L224","article-title":"Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia","volume":"43","author":"Keegan","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.thromres.2011.11.041_bb0350","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/CCM.0b013e3181932394","article-title":"Argatroban for anticoagulation in continuous renal replacement therapy","volume":"37","author":"Link","year":"2009","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.thromres.2011.11.041_bb0355","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/CCM.0b013e3181a6009a","article-title":"Argatroban for anticoagulation in continuous renal replacement therapy (the authors reply)","volume":"37","author":"Link","year":"2009","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.thromres.2011.11.041_bb0360","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1345\/aph.1G033","article-title":"Argatroban anticoagulation in patients with heparin-induced thrmbocytopenia requiring renal replacement therapy","volume":"39","author":"Reddy","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.thromres.2011.11.041_bb0365","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1523-1755.2004.66022.x","article-title":"A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease","volume":"66","author":"Murray","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.thromres.2011.11.041_bb0370","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0003-4975(02)04309-6","article-title":"Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use","volume":"75","author":"Lubenow","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.thromres.2011.11.041_bb0375","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1213\/01.ANE.0000146940.47989.5F","article-title":"The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia","volume":"100","author":"Hallman","year":"2005","journal-title":"Anesth Analg"},{"key":"10.1016\/j.thromres.2011.11.041_bb0380","first-page":"A132","article-title":"Argatroban for anticoagulation in children with heparin-induced platelet antibodies.[abstr]","volume":"31","author":"Liedel","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.thromres.2011.11.041_bb0385","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.mph.0000195296.48319.38","article-title":"Argatroban anticoagulation in pediatric patients","volume":"28","author":"Hursting","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.thromres.2011.11.041_bb0390","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pbc.22852","article-title":"Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokintec study","volume":"56","author":"Young","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.thromres.2011.11.041_bb0395","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0889-8588(05)70144-1","article-title":"Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation","volume":"14","author":"Kawada","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.thromres.2011.11.041_bb0400","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2491\/jjsth.11.201","article-title":"Use of an antithrombotic agent, argatroban, in two patients with ECMO after pediatric open heart surgery","volume":"11","author":"Okada","year":"2000","journal-title":"Jpn J Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.thromres.2011.11.041_bb0475","first-page":"1494","article-title":"Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: a likely under-recognized complication with significant morbidity and mortality: report of 4 sequential cases","author":"Boshkov","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.thromres.2011.11.041_bb0480","first-page":"1495","article-title":"Report of argatroban infusions for heparin-induced thrombocytopenia (HIT) diagnosed by functional assay in 2 congenital cardiac surgery patients, a neonate and a 5 month old","author":"Boshkov","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.11.041_bb0415","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.PCC.0000231946.88688.07","article-title":"Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporal membrane oxygenation managed with argatroban","volume":"7","author":"Scott","year":"2006","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.thromres.2011.11.041_bb0420","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPH.0b013e3180463626","article-title":"Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporal life support","volume":"29","author":"Potter","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.thromres.2011.11.041_bb0425","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/107602960501100306","article-title":"Transitioning from aragtroban to warfarin therapy in patients with heparin-induced thrombocytopenia","volume":"11","author":"Hursting","year":"2005","journal-title":"Clin Appl Thrombosis\/Hemostasis"},{"key":"10.1016\/j.thromres.2011.11.041_bb0430","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1160\/TH03-12-0794","article-title":"Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time and ecarin clotting time","volume":"91","author":"Harder","year":"2004","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811006372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811006372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T22:08:45Z","timestamp":1640038125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384811006372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0049384811006372"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2011.11.041","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}